Aspire Biopharma Holdings, Inc. ASBP
7.27 USD -0.03 (-0.41%)
At closeNov 3, 2026, 4:00 PM EST
7.27 0.00 0.00%
After hours · Nov 3, 4:00 PM ET
6.96 Day range 7.80
0.11 52-week range 14.40
- YTD
- +37.69%
- 1 year
- -49.79%
Financial health
Altman Z-Score
-3.49 Distress zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
5 / 9 Average
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
C2 / 5 overall
- DCF 1
- Return on Equity 1
- Return on Assets 1
- Debt / Equity 1
- P/E 1
- P/B 5
Valuation
P/E -9.7×
FY 2021 5y median -9.7× FY 2025
P/S 38181×
FY 2021 5y median 0.0× FY 2025
P/B -37.1×
FY 2021 5y median -37.1× FY 2025
P/FCF -48.1×
FY 2021 5y median -2204× FY 2025
EV/EBITDA -20.9×
FY 2021 5y median -20.9× FY 2025
EV/Sales 38243×
FY 2021 5y median 0.0× FY 2025
FCF Yield -2.1%
FY 2021 5y median -0.0% FY 2025
Profitability
Gross Margin -1.9%
FY 2021 5y median 0.0% FY 2025
Operating Margin -312016.9%
FY 2021 5y median 0.0% FY 2025
Net Margin -394725.1%
FY 2021 5y median 0.0% FY 2025
ROE 383.9%
FY 2021 5y median 85.1% FY 2025
ROIC 395.3%
FY 2021 5y median -4.8% FY 2025
ROA -1865.7%
FY 2021 5y median -8.7% FY 2025
Growth (YoY)
Revenue 0.0%
FY 2021 FY 2025
Operating Income -1498.1%
FY 2021 FY 2025
EPS (diluted) 52.1%
FY 2021 FY 2025
Free Cash Flow -1756.6%
FY 2021 FY 2025
Financial Health
Current Ratio 0.2×
FY 2021 5y median 0.2× FY 2025
Quick Ratio 0.1×
FY 2021 5y median 0.2× FY 2025
Debt / Equity -0.2×
FY 2021 5y median -0.2× FY 2025
Net Debt / EBITDA -0.0×
FY 2021 5y median 0.0× FY 2025
Interest Coverage -2.3×
FY 2021 5y median -2.3× FY 2025
Dividends
Dividend Yield 0.0%
FY 2021 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2021 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31